Movement Alert｜Vertex Pharmaceuticals Rises 3.05% in Regular Trading, Q2 Revenue Beats Estimates and Full-Year Guidance Raised

Market Focus08-04 22:15

On August 4, Vertex Pharmaceuticals rose 3.05% in regular trading, trading at 480.71 USD/share, with turnover of $151 million. The rally was driven by the company's strong Q2 earnings report and an upward revision to full-year guidance.

Vertex reported Q2 adjusted EPS of $4.73, up 4.65% year-over-year, in line with analyst expectations of $4.74. Revenue reached $3.334 billion, up 12.5% year-over-year, beating the FactSet consensus estimate of $3.232 billion by approximately $100 million. More importantly, the company raised its full-year revenue guidance to $13.1 billion-$13.2 billion from the prior range of $12.95 billion-$13.1 billion, surpassing the Street estimate of $13.06 billion. Meanwhile, GAAP and non-GAAP R&D and SG&A expense guidance remained unchanged.

Following the results, Cantor Fitzgerald raised its price target to $595 from $590, maintaining an Overweight rating. Goldman Sachs had previously lifted its target to $652 with a Buy rating. The average analyst price target stands at $563.12 per FactSet.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119423032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119423032","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Vertex Pharmaceuticals Rises 3.05% in Regular Trading, Q2 Revenue Beats Estimates and Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 4, Vertex Pharmaceuticals rose 3.05% in regular trading, trading at 480.71 USD/share, with turnover of $151 million. The rally was driven by the company's strong Q2 earnings report and an upward revision to full-year guidance.</p><p>Vertex reported Q2 adjusted EPS of $4.73, up 4.65% year-over-year, in line with analyst expectations of $4.74. Revenue reached $3.334 billion, up 12.5% year-over-year, beating the FactSet consensus estimate of $3.232 billion by approximately $100 million. More importantly, the company raised its full-year revenue guidance to $13.1 billion-$13.2 billion from the prior range of $12.95 billion-$13.1 billion, surpassing the Street estimate of $13.06 billion. Meanwhile, GAAP and non-GAAP R&D and SG&A expense guidance remained unchanged.</p><p>Following the results, Cantor Fitzgerald raised its price target to $595 from $590, maintaining an Overweight rating. Goldman Sachs had previously lifted its target to $652 with a Buy rating. The average analyst price target stands at $563.12 per FactSet.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Vertex Pharmaceuticals Rises 3.05% in Regular Trading, Q2 Revenue Beats Estimates and Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Vertex Pharmaceuticals Rises 3.05% in Regular Trading, Q2 Revenue Beats Estimates and Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, Vertex Pharmaceuticals rose 3.05% in regular trading, trading at 480.71 USD/share, with turnover of $151 million. The rally was driven by the company's strong Q2 earnings report and an upward revision to full-year guidance.</p><p>Vertex reported Q2 adjusted EPS of $4.73, up 4.65% year-over-year, in line with analyst expectations of $4.74. Revenue reached $3.334 billion, up 12.5% year-over-year, beating the FactSet consensus estimate of $3.232 billion by approximately $100 million. More importantly, the company raised its full-year revenue guidance to $13.1 billion-$13.2 billion from the prior range of $12.95 billion-$13.1 billion, surpassing the Street estimate of $13.06 billion. Meanwhile, GAAP and non-GAAP R&D and SG&A expense guidance remained unchanged.</p><p>Following the results, Cantor Fitzgerald raised its price target to $595 from $590, maintaining an Overweight rating. Goldman Sachs had previously lifted its target to $652 with a Buy rating. The average analyst price target stands at $563.12 per FactSet.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1119423032","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119423032","pubTimestamp":1785852919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, Vertex Pharmaceuticals rose 3.05% in regular trading, trading at 480.71 USD/share, with turnover of $151 million. The rally was driven by the company's strong Q2 earnings report and an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"走势警报|Vertex Pharmaceuticals 常规交易上涨 3.05%，第二季度收入超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"On August 4, Vertex Pharmaceuticals rose 3.05% in regular trading, trading at 480.71 USD/share, with turnover of $151 million. The rally was driven by the company's strong Q2 earnings report and an upward revision to full-year guidance.Vertex reported Q2 adjusted EPS of $4.73, up 4.65% year-over-year, in line with analyst expectations of $4.74. Revenue reached $3.334 billion, up 12.5% year-over-year, beating the FactSet consensus estimate of $3.232 billion by approximately $100 million. More importantly, the company raised its full-year revenue guidance to $13.1 billion-$13.2 billion from the prior range of $12.95 billion-$13.1 billion, surpassing the Street estimate of $13.06 billion. Meanwhile, GAAP and non-GAAP R&D and SG&A expense guidance remained unchanged.Following the results, Cantor Fitzgerald raised its price target to $595 from $590, maintaining an Overweight rating. Goldman Sachs had previously lifted its target to $652 with a Buy rating. The average analyst price target stands at $563.12 per FactSet.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119423032","isCrawlerRequest":true}